us.eisai.com Open in urlscan Pro
208.74.145.245  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * VIEW CLINICAL TRIALS
 * MEDIA CENTER
 * CONTACT US


menu
 * WHO WE ARE
    * hhc Mission
    * Corporate Responsibility
    * Locations
    * Leadership
    * Our History
    * Collaborations

 * OUR SCIENCE
    * Global Pipeline
    * Disease Areas
    * Clinical Trials
    * Discovery Centers

 * OUR MEDICINES
    * Our Products
    * Manufacturing
    * Eisai Medical Information
    * Pharmacy Trade Relations

 * OUR PATIENT FOCUS
    * Community Involvement
    * Magnolia Patient Support Programs
    * Eisai USA Foundation
    * Eisai Grants Programs

 * CAREERS
    * Find Your Opportunity
    * Talent Areas
    * Life at Eisai
    * Career Growth & Development
    * Rewards & Benefits
    * Diversity & Inclusion

 * 

 * VIEW CLINICAL TRIALS
 * MEDIA CENTER
 * CONTACT US


SEARCH <br />EISAI FOR... SEARCH
 1. Home
    >
 2. Our Science
    >
 3. Discovery Centers
    >
 4. EPAT
    >

 
back
Click
 * EPAT EPAT
   * Residue-Specific Conjugation Technology (RESPECT®)
   * Proprietary Cytotoxic Payload Technology


WHAT IF WE COULD CREATE PRECISION ANTI-CANCER MEDICINES THAT TARGET TUMOR CELLS?

That’s the goal at Epochal Precision Anti-Cancer Therapeutics (EPAT), our
Biologics Discovery Center located in Exton, Pennsylvania. EPAT is developing
precision oncology therapies by combining biologics expertise, Eisai’s unique
Antibody-Drug Conjugate (ADC) technology, proprietary payloads and bispecific
antibodies.

--------------------------------------------------------------------------------


OUR GOAL: IMPROVED RESULTS WITH FEWER SIDE EFFECTS

EPAT is focused on developing breakthrough therapies for patients living with a
variety of cancers, especially in these key areas of unmet medical need:

 * Women’s cancers, including gynecologic cancers and breast cancer
 * Stroma-rich malignant cancers, including pancreatic cancer, triple negative
   breast cancer and scirrhous gastric cancer


HERE’S HOW ADCS ATTACK CANCER CELLS WITH PRECISION.

ADCs are next-generation biopharmaceutical drugs consisting of targeted
molecular antibodies linked to anti-cancer drugs. An ADC is designed to target
and bind to specific cancer cells, then release the anti-cancer “warhead” into
the cancer cells to cause cell death (apoptosis), followed by “bystander
effects” on the surrounding cells. The hope behind this “smart” approach is both
to maximize bystander effects on the tumor microenvironment and to minimize
bystander effects on healthy cells , leading to fewer unintended side effects.
Our first ADC drug, MORAb-202, is now being developed in clinical phase 1 study
in Japan .

--------------------------------------------------------------------------------


LEARN THE ABCS OF ADCS

Eribulin* ADC Payload

A


ADC LATCHES ONTO CANCER CELL


B


CELL INTERNALIZES ADC AND ITS PAYLOAD


C


WARHEAD (ERIBULIN) IS RELEASED



--------------------------------------------------------------------------------

*Any ADC employing eribulin as a payload is investigational and has not been
approved by regulatory authorities. For more information on HALAVEN® (eribulin
mesylate), please see www.halaven.com or contact Eisai’s Medical Information
toll-free number: 1-888-274-2378.


EXPLORE THE SCIENCE BEHIND EPAT’S NEXT-GENERATION PROGRAMS

Get an in-depth look at EPAT’s proprietary technologies, including:



RESIDUE-SPECIFIC CONJUGATION TECHNOLOGY (RESPECT®)

PROPRIETARY CYTOTOXIC PAYLOAD TECHNOLOGY

EPAT PLAYS A KEY ROLE IN WORKING TOWARDS DISCOVERING INNOVATIVE BREAKTHROUGHS BY
COMBINING OUR BIOLOGICS-BASED PRECISION MEDICINES WITH EISAI’S VAST KNOWLEDGE OF
CHEMICALS AND GENETICS.

Toshimitsu Uenaka
President, EPAT

WHO WE ARE
 * hhc Mission
 * Our Locations
 * Corporate Responsibility   
 * Leadership
 * Our History
 * Collaboration

OUR SCIENCE
 * Global Pipeline
 * Disease Areas
 * Clinical Trials
 * Discovery
   Centers

OUR MEDICINES
 * Our Products
 * Manufacturing
 * Eisai Medical Information
 * Pharmacy Trade Relations

OUR PATIENT FOCUS
 * Community Involvement   
 * Magnolia Patient Support
 * Eisai USA Foundation
 * Eisai Grants Programs

CAREERS AT EISAI
 * Find Your Opportunity
 * Talent Areas
 * Life at Eisai
 * Career Growth & Development
 * Rewards & Benefits
 * Diversity & Inclusion

MEDIA CENTER CONTACT US VIEW CLINICAL TRIALS

Site Map US Privacy Policy EU/UK Privacy Policy Legal Notices & Industry
Practices Eisai Co. Ltd. Eisai CA Eisai EU

This is the website of Eisai Inc., a US company. This site is intended for US
residents only. The health information contained
herein is provided for educational purposes only and is not intended to replace
discussions with a health care provider. All
decisions regarding patient care must be made with a health care provider,
considering the unique characteristics of the patient.

US2639  |  Copyright ©Eisai Inc. 2022. All Rights Reserved.



YOU’RE ABOUT TO LEAVE US.EISAI.COM

By clicking on the CONTINUE button you will be leaving the Eisai Inc. U.S.
website. Eisai assumes no responsibility for, and exercises no control over, the
accuracy or information on this external website.


Continue

Cancel